Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information Or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Prevalence Of Genetic And Other Target Diseases
3.2.1.2. Increasing Focus On Development Of Targeted Drugs And Personalized Medicine
3.2.1.3. Technological Advancements In Genotyping Techniques
3.2.1.4. Increase In Funding In Genomics
3.2.2. Market Restraint Analysis
3.2.2.1. Lack Of Skilled Labor
3.2.2.2. Ambiguous Reimbursement Policies
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Genotyping Market: Product Movement Analysis
4.2. Instruments
4.2.1. Instruments Market, 2018 – 2030 (USD Million)
4.3. Reagents & Kits
4.3.1. Reagents & Kits Market, 2018 – 2030 (USD Million)
4.4. Software and Services
4.4.1. Software and Services Market, 2018 – 2030 (USD Million)
Chapter 5. Technology Business Analysis
5.1. Genotyping Market: Technology Movement Analysis
5.2. PCR
5.2.1. PCR Market, 2018 – 2030 (USD Million)
5.3. Capillary Electrophoresis
5.3.1. Capillary Electrophoresis Market, 2018 – 2030 (USD Million)
5.4. Microarrays
5.4.1. Microarrays Market, 2018 – 2030 (USD Million)
5.5. Sequencing
5.5.1. Sequencing Market, 2018 – 2030 (USD Million)
5.6. Mass Spectrometry
5.6.1. Mass Spectrometry Market, 2018 – 2030 (USD Million)
5.7. Others
5.7.1. Other Technologies Market, 2018 – 2030 (USD Million)
Chapter 6. Application Business Analysis
6.1. Genotyping Market: Application Movement Analysis
6.2. Pharmacogenomics
6.2.1. Pharmacogenomics Market, 2018 – 2030 (USD Million)
6.3. Diagnostics and Personalized Medicine
6.3.1. Diagnostics and Personalized Medicine Market, 2018 – 2030 (USD Million)
6.4. Agricultural Biotechnology
6.4.1. Agricultural Biotechnology Market, 2018 – 2030 (USD Million)
6.5. Animal Genetics
6.5.1. Animal Genetics Market, 2018 – 2030 (USD Million)
6.6. Others
6.6.1. Other Application Market, 2018 – 2030 (USD Million)
Chapter 7. End-Use Business Analysis
7.1. Genotyping Market: End-use Movement Analysis
7.2. Pharmaceutical and Biopharmaceutical Companies
7.2.1. Pharmaceutical and Biopharmaceutical Companies Market, 2018 – 2030 (USD Million)
7.3. Diagnostics and Research Laboratories
7.3.1. Diagnostics and Research Laboratories Market, 2018 – 2030 (USD Million)
7.4. Academic Institutes
7.4.1. Academic Institutes Market, 2018 – 2030 (USD Million)
7.5. Others
7.5.1. Other End-use Market, 2018 – 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Genotyping Market Share By Region, 2022 & 2030
8.2. North America
8.2.1. SWOT Analysis
8.2.2. North America Genotyping Market, 2018 – 2030 (USD Million)
8.2.3. U.S.
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. U.S. Genotyping Market, 2018 – 2030 (USD Million)
8.2.4. Canada
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Competitive Scenario
8.2.4.4. Regulatory Framework
8.2.4.5. Canada Genotyping Market, 2018 – 2030 (USD Million)
8.3. Europe
8.3.1. SWOT Analysis
8.3.2. Europe Genotyping Market, 2018 – 2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. UK Genotyping Market, 2018 – 2030 (USD Million)
8.3.4. Germany
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Germany Genotyping Market, 2018 – 2030 (USD Million)
8.3.5. France
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. France Genotyping Market, 2018 – 2030 (USD Million)
8.3.6. Italy
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Italy Genotyping Market, 2018 – 2030 (USD Million)
8.3.7. Spain
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Spain Genotyping Market, 2018 – 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Denmark Genotyping Market, 2018 – 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Sweden Genotyping Market, 2018 – 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Target Disease Prevalence
8.3.10.3. Competitive Scenario
8.3.10.4. Regulatory Framework
8.3.10.5. Norway Genotyping Market, 2018 – 2030 (USD Million)
8.4. Asia Pacific
8.4.1. SWOT Analysis
8.4.2. Asia Pacific Genotyping Market, 2018 – 2030 (USD Million)
8.4.3. Japan
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Japan Genotyping Market, 2018 – 2030 (USD Million)
8.4.4. China
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. China Genotyping Market, 2018 – 2030 (USD Million)
8.4.5. India
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. India Genotyping Market, 2018 – 2030 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Australia Genotyping Market, 2018 – 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Thailand Genotyping Market, 2018 – 2030 (USD Million)
8.4.8. South Korea
8.4.8.1. Key Country Dynamics
8.4.8.2. Target Disease Prevalence
8.4.8.3. Competitive Scenario
8.4.8.4. Regulatory Framework
8.4.8.5. South Korea Genotyping Market, 2018 – 2030 (USD Million)
8.5. Latin America
8.5.1. SWOT Analysis
8.5.2. Latin America Genotyping Market, 2018 – 2030 (USD Million)
8.5.3. Brazil
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Brazil Genotyping Market, 2018 – 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Mexico Genotyping Market, 2018 – 2030 (USD Million)
8.5.5. Argentina
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Competitive Scenario
8.5.5.4. Regulatory Framework
8.5.5.5. Argentina Genotyping Market, 2018 – 2030 (USD Million)
8.6. MEA
8.6.1. SWOT Analysis
8.6.2. MEA Genotyping Market, 2018 – 2030 (USD Million)
8.6.3. South Africa
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. South Africa Genotyping Market, 2018 – 2030 (USD Million)
8.6.4. Saudi Arabia
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Saudi Arabia Genotyping Market, 2018 – 2030 (USD Million)
8.6.5. UAE
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. UAE Genotyping Market, 2018 – 2030 (USD Million)
8.6.6. Kuwait
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Competitive Scenario
8.6.6.4. Regulatory Framework
8.6.6.5. Kuwait Genotyping Market, 2018 – 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Strategy Mapping
9.3. Company Market Share Analysis, 2022
9.4. Company Profiles/Listing
9.4.1. Thermo Fisher Scientific, Inc.
9.4.1.1. Overview
9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Illumina, Inc.
9.4.2.1. Overview
9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. QIAGEN
9.4.3.1. Overview
9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. F. Hoffmann-La Roche Ltd.
9.4.4.1. Overview
9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Fluidigm Corporation
9.4.5.1. Overview
9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Danaher Corporation
9.4.6.1. Overview
9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Agilent Technologies
9.4.7.1. Overview
9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Eurofins Scientific Inc.
9.4.8.1. Overview
9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. GE Healthcare Inc.
9.4.9.1. Overview
9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Bio-Rad Laboratories Inc.
9.4.10.1. Overview
9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer